PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Risk Reduction Strategies in Breast Cancer Prevention.

Abstract Evaluating the risk of breast cancer makes it possible to identify women with a high risk of developing breast cancer in the future. Adopting a healthier lifestyle, involving diet and exercise, is one way of reducing this risk-but there are other, non-modifiable risk factors, such as family history, genetics and diagnosis of premalignant lesions. In this high-risk population, the tracking must be rigorous and involve the participation of the patient herself, earlier and more frequent clinical assessment, and the use of imaging screening. Agents such as tamoxifen, raloxifene and aromatase inhibitors may be used in chemoprevention and may reduce the risk substantially. The risks and benefits must be assessed, and one must discuss with the patient her adverse events and the decision regarding the best treatment. Women who carry the BRCA1/2 mutation (very high risk) can benefit from prophylactic surgical interventions, such as bilateral mastectomy and/or bilateral salpingo-oophorectomy. This group of patients must be monitored by a multidisciplinary team, providing explanations prior to surgery regarding the surgical treatment offered, the reconstruction techniques, and the risks and complications.
PMID
Related Publications

Prevention with tamoxifen or other hormones versus prophylactic surgery in BRCA1/2-positive women: a decision analysis.

Breast cancer and ovarian cancer genetics.

Current strategies for the prevention of breast cancer.

Risk-reducing strategies for women carrying BRCA1/2 mutations with a focus on prophylactic surgery.

Risk-reducing strategies for breast cancer--a review of recent literature.

Authors

Mayor MeshTerms
Keywords

Breast

mastectomy

risk

serm oophorectomy

Journal Title european journal of breast health
Publication Year Start




PMID- 28894848
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20170912
LR  - 20170914
IS  - 2587-0831 (Print)
IS  - 1306-0945 (Linking)
VI  - 13
IP  - 3
DP  - 2017 Jul
TI  - Risk Reduction Strategies in Breast Cancer Prevention.
PG  - 103-112
LID - 10.5152/ejbh.2017.3583 [doi]
AB  - Evaluating the risk of breast cancer makes it possible to identify women with a
      high risk of developing breast cancer in the future. Adopting a healthier
      lifestyle, involving diet and exercise, is one way of reducing this risk-but
      there are other, non-modifiable risk factors, such as family history, genetics
      and diagnosis of premalignant lesions. In this high-risk population, the tracking
      must be rigorous and involve the participation of the patient herself, earlier
      and more frequent clinical assessment, and the use of imaging screening. Agents
      such as tamoxifen, raloxifene and aromatase inhibitors may be used in
      chemoprevention and may reduce the risk substantially. The risks and benefits
      must be assessed, and one must discuss with the patient her adverse events and
      the decision regarding the best treatment. Women who carry the BRCA1/2 mutation
      (very high risk) can benefit from prophylactic surgical interventions, such as
      bilateral mastectomy and/or bilateral salpingo-oophorectomy. This group of
      patients must be monitored by a multidisciplinary team, providing explanations
      prior to surgery regarding the surgical treatment offered, the reconstruction
      techniques, and the risks and complications.
FAU - Costa, Mauricio
AU  - Costa M
AD  - Americas Medical City, Breast Center, Rio de Janeiro, Brazil.
FAU - Saldanha, Paula
AU  - Saldanha P
AD  - Americas Medical City, Breast Center, Rio de Janeiro, Brazil.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20170701
PL  - Turkey
TA  - Eur J Breast Health
JT  - European journal of breast health
JID - 101709357
PMC - PMC5544140
OTO - NOTNLM
OT  - Breast
OT  - mastectomy
OT  - risk
OT  - serm oophorectomy
COI - Conflict of Interest: No conflict of interest was declared by the author.
EDAT- 2017/09/13 06:00
MHDA- 2017/09/13 06:01
CRDT- 2017/09/13 06:00
PHST- 2017/05/15 [received]
PHST- 2017/06/19 [accepted]
AID - 10.5152/ejbh.2017.3583 [doi]
AID - jbh-13-3-103 [pii]
PST - epublish
SO  - Eur J Breast Health. 2017 Jul 1;13(3):103-112. doi: 10.5152/ejbh.2017.3583.
      eCollection 2017 Jul.